Treatment of stable chronic bronchitis with iodinated glycerol: a double-blind, placebo-controlled trial.

Abstract

In a double-blind trial, 29 patients were treated for stable, chronic bronchitis with iodinated glycerol (Organidin, 60 mg four times daily; n = 16) or placebo (n = 13). The study consisted of a 2-week single-blind lead-in period, followed by a 6-week double-blind treatment period, and assessed a total of 50 response variables. In this set of patients, treatment with iodinated glycerol was associated with statistically significant (P < 0.05) and/or positive trend (P < 0.1) toward improvement in cough frequency, cough severity, difficulty in raising sputum, sputum thickness, sputum stickiness, forced expiratory flow at FVC25%-75%, cell concentration in sputum, and several measures of physician assessment of patient condition. Iodinated glycerol was well tolerated during the 6-week treatment period; no adverse effects were reported and no patient receiving iodinated glycerol withdrew from the study prematurely. In conclusion, this study demonstrates that iodinated glycerol, 60-mg tablets given in a total daily dose of 240 mg, is safe and effective therapy for reducing symptoms in patients with stable, chronic bronchitis.

• Authors: L H Repsher
• Journal: Journal of clinical pharmacology (J Clin Pharmacol) Vol. 33 Issue 9 Pg. 856-60 (Sep 1993) ISSN: 0091-2700 [Print] England
• PMID: 8227484 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Expectorants
• iodinated glycerol
• Glycerol

Topics

• Adult
• Bronchitis (drug therapy, pathology)
• Chronic Disease
• Cough (pathology)
• Double-Blind Method
• Expectorants (therapeutic use)
• Female
• Glycerol (analogs & derivatives, therapeutic use)
• Humans
• Male
• Maximal Midexpiratory Flow Rate
• Sputum (drug effects, metabolism)